Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Authors' conclusion
In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.
Study context
- Population
- Adults with body-mass index (BMI) ≥30, or BMI 27 to <30 plus ≥1 weight-related condition; 51.8% menrandomized 2:1:1:1:1:2:2
- Participants
- 338 adults
- Comparison
- Once-weekly subcutaneous retatrutide vs placebo for 48 weeks
- Primary endpoint
- Percentage change in body weight from baseline
- Follow-up
- 24 weeks
Methodological detailsphase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Least-squares mean percentage change in body weight
1 mg
−7.2%
least-squares mean
Combined 4 mg
−12.9%
least-squares mean
Combined 8 mg
−17.3%
least-squares mean
12 mg
−17.5%
least-squares mean
Placebo
−1.6%
least-squares mean
Secondary outcomes
| Outcome | Values |
|---|---|
| Least-squares mean percentage change in body weight · 48 weeks | 1 mg least-squares mean −8.7% · Combined 4 mg least-squares mean −17.1% · Combined 8 mg least-squares mean −22.8% · 12 mg least-squares mean −24.2% · Placebo least-squares mean −2.1% |
| Weight reduction ≥5% · 48 weeks | Combined 4 mg 92% · Combined 8 mg 100% · 12 mg 100% · Placebo 27% |
| Weight reduction ≥10% · 48 weeks | Combined 4 mg 75% · Combined 8 mg 91% · 12 mg 93% · Placebo 9% |
| Weight reduction ≥15% · 48 weeks | Combined 4 mg 60% · Combined 8 mg 75% · 12 mg 83% · Placebo 2% |
Safety
Adverse events
- Most common AEs with retatrutide were gastrointestinal: dose-related, mostly mild to moderate, partially mitigated with lower starting dose (2 mg vs 4 mg)
- Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter
Original publication
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →